Molecules | |
Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey | |
Gaëlle Mariaule1  | |
[1] Institut Curie, UMR CNRS 176, 26 rue d’Ulm, Paris 75005, France; E-Mail: | |
关键词: CDK; kinase; inhibitor; anticancer; heterocycle; clinical evaluation; ATP-competitive; allosteric site; ATP non-competitive; | |
DOI : 10.3390/molecules190914366 | |
来源: mdpi | |
【 摘 要 】
In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied, none of the compounds commercialized since then target cyclin-dependent kinases (CDKs). Following a recent and detailed review on the subject by Galons
【 授权许可】
CC BY
© 2014 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190021643ZK.pdf | 938KB | download |